Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease - PubMed (original) (raw)
Review
. 1995 Sep;24(3):475-507.
Affiliations
- PMID: 8809232
Review
Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease
R B Sartor. Gastroenterol Clin North Am. 1995 Sep.
Abstract
Although the causes, events initiating and triggering inflammation, and the precise immunoregulatory defects of IBD are still not known, investigations have provided a better understanding of the mechanisms of perpetuation of inflammation, genetic susceptibility, tissue injury, and symptoms. Ulcerative colitis and Crohn's disease are related disorders that probably share susceptibility genes and have similar nonspecific inflammatory mediator profiles. These diseases, however, almost certainly have different causes and respond to different antigenic stimuli. It is probable that both ulcerative colitis and Crohn's disease represent heterogenic groups of diseases that share similar mechanisms of tissue damage but have different initiating events and immunoregulatory abnormalities. Rodent models demonstrate that a wide variety of initial injuries or perturbations of immunoregulatory pathways can lead to similar phenotypes of intestinal injury, and human studies show evidence of genetic heterogeneity. It is equally apparent from these models that initiating and perpetuating mechanisms are entirely distinct and that the intestine has a remarkable ability to heal. Chronicity of disease depends on continued exposure to toxic luminal components, most commonly of bacterial origin, and genetically determined host susceptibility. Precise mechanisms of differential genetic susceptibility remain unclear, but defective down-regulation of inflammation is consistent with clinical and experimental observations. The author proposes the following sequence of events (Fig. 9). Nonspecific intestinal inflammation can be induced by a wide variety of enteric infections or ingested toxins. Resultant increased mucosal permeability leads to enhanced uptake of toxic luminal bacterial products, which potentiate local injury. The vast majority of hosts respond to these injurious events by promptly down-regulating the inflammatory response and rapidly healing the mucosal damage without residual scarring. The genetically susceptible host, however, who lacks the ability to suppress the inflammatory response efficiently, has inappropriate amplification of the immune cascade. In response to constant exposure to phlogistic luminal constituents, these patients develop an unrestrained inflammatory response, leading to tissue destruction, chronic inflammation, and fibrosis. Thus, IBD is caused by a genetically determined defective down-regulation of inflammation driven by ubiquitous antigens. Luminal anaerobic bacterial antigens are the stimuli in Crohn's disease, but ulcerative colitis may be caused by functionally abnormal aerobic bacteria or primary defects in epithelial cell physiology. Spontaneous or therapy-induced remissions can be achieved, but the risk of reactivation of inflammation is high because of the frequent exposure to triggering episodes that can reignite the inflammatory cascade. [formula: see text] This theory suggests that the intestine is in a constant state of controlled inflammation, mediated by a balance between aggressive luminal forces and host protective mechanisms (Fig. 10). This delicate balance can be deranged by any number of environmental triggering events and is in dysequilibrium in IBD. Amplification of the inflammatory response activates effector cells and cascades of soluble inflammatory molecules, which mediate tissue injury and physiologic responses leading to symptoms of IBD. These relatively nonspecific events are the target of most current therapeutic agents, which can inhibit but not completely block intestinal inflammation because of the overwhelming number of parallel pathways involved. Specific inhibition of selected effector molecules is intellectually intriguing but is less likely to paralyze the inflammatory response during clinically apparent inflammation than is blockade of key immunoregulatory cells and molecules. Better understanding of initiating, perpetuating, and immunoregulatory mechanisms should provide more
Similar articles
- Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.
Sartor RB. Sartor RB. Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390-407. doi: 10.1038/ncpgasthep0528. Nat Clin Pract Gastroenterol Hepatol. 2006. PMID: 16819502 Review. - Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases.
Sartor RB. Sartor RB. Am J Gastroenterol. 1997 Dec;92(12 Suppl):5S-11S. Am J Gastroenterol. 1997. PMID: 9395346 Review. - Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications.
Balfour Sartor R. Balfour Sartor R. J Clin Gastroenterol. 2007 May-Jun;41 Suppl 1:S37-43. doi: 10.1097/MCG.0b013e31802db364. J Clin Gastroenterol. 2007. PMID: 17438417 Review. - Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy.
Fiocchi C. Fiocchi C. Minerva Gastroenterol Dietol. 2002 Sep;48(3):215-26. Minerva Gastroenterol Dietol. 2002. PMID: 16491045
Cited by
- The Impact of the CB2 Cannabinoid Receptor in Inflammatory Diseases: An Update.
Rakotoarivelo V, Mayer TZ, Simard M, Flamand N, Di Marzo V. Rakotoarivelo V, et al. Molecules. 2024 Jul 18;29(14):3381. doi: 10.3390/molecules29143381. Molecules. 2024. PMID: 39064959 Free PMC article. Review. - Gene coexpression networks reveal a broad role for lncRNAs in inflammatory bowel disease.
Johnson JL, Sargsyan D, Neiman EM, Hart A, Stojmirovic A, Kosoy R, Irizar H, Suárez-Fariñas M, Song WM, Argmann C, Avey S, Shmuel-Galia L, Vierbuchen T, Bongers G, Sun Y, Edelstein L, Perrigoue J, Towne JE, Hall AO, Fitzgerald KA, Hoebe K. Johnson JL, et al. JCI Insight. 2024 Feb 8;9(3):e168988. doi: 10.1172/jci.insight.168988. JCI Insight. 2024. PMID: 38329124 Free PMC article. - Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.
Saadh MJ, Mikhailova MV, Rasoolzadegan S, Falaki M, Akhavanfar R, Gonzáles JLA, Rigi A, Kiasari BA. Saadh MJ, et al. Eur J Med Res. 2023 Jan 27;28(1):47. doi: 10.1186/s40001-023-01008-7. Eur J Med Res. 2023. PMID: 36707899 Free PMC article. Review. - The Evaluation of Transmural Healing by Low-dose Computed Tomography Enterography in Patients with Crohn's Disease.
Fujimura H, Hashimoto S, Shimizu K, Onoda H, Tanabe M, Higashi M, Ogawa R, Goto A, Hamabe K, Nishikawa J, Ito K, Takami T. Fujimura H, et al. Intern Med. 2022;61(20):2999-3007. doi: 10.2169/internalmedicine.9066-21. Epub 2022 Oct 15. Intern Med. 2022. PMID: 36244733 Free PMC article. - Network Pharmacology-Based Strategy to Identify the Pharmacological Mechanisms of Pulsatilla Decoction against Crohn's Disease.
Liu J, Zhang L, Wang Z, Chen S, Feng S, He Y, Zhang S. Liu J, et al. Front Pharmacol. 2022 Apr 5;13:844685. doi: 10.3389/fphar.2022.844685. eCollection 2022. Front Pharmacol. 2022. PMID: 35450039 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical